MNG406
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.717
- INTERFERON_GAMMA_RESPONSE+0.619
- ALLOGRAFT_REJECTION+0.398
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.376
- PEROXISOME+0.331
- IL6_JAK_STAT3_SIGNALING+0.309
- COMPLEMENT+0.270
- IL2_STAT5_SIGNALING+0.264
- DNA_REPAIR+0.250
- ADIPOGENESIS+0.246
Top 10 suppressed
- ANGIOGENESIS-0.388
- PANCREAS_BETA_CELLS-0.324
- SPERMATOGENESIS-0.209
- HYPOXIA-0.203
- TNFA_SIGNALING_VIA_NFKB-0.159
- CHOLESTEROL_HOMEOSTASIS-0.124
- KRAS_SIGNALING_DN-0.097
- GLYCOLYSIS-0.087
- ESTROGEN_RESPONSE_EARLY-0.056
- HEDGEHOG_SIGNALING-0.044
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG181 | — | — | 0.819 |
| 2 | TCGA-CQ-5327-01A-01R-1686-07 | — | — | 0.782 |
| 3 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.780 |
| 4 | TCGA-CQ-5331-01A-02R-1873-07 | — | — | 0.765 |
| 5 | TCGA-55-8301-01A-11R-2287-07 | — | cohortA1 | 0.760 |
| 6 | MNG57 | — | — | 0.760 |
| 7 | TCGA-22-5474-01A-01R-1635-07 | — | cohortSQ2 | 0.759 |
| 8 | 896B5096-D888-4DC3-9C70-152BDE083E26 | — | — | 0.758 |
| 9 | MNG596 | — | — | 0.753 |
| 10 | SRR934833 | — | — | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.717 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.619 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.398 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.376 | Inavolisib | — uncovered |
| PEROXISOME | 0.331 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.309 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.264 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.246 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.225 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.217 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.215 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.190 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.155 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.135 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.131 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.108 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.096 | Inavolisib | — uncovered |